Akintunde Rasaq Akinleye, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

None Reported

None Reported

MEK and the inhibitors: from bench to bedside
J Hematol Oncol
Date: 04 2013

Novel agents for chronic lymphocytic leukemia
J Hematol Oncol
Date: 05 2013

Ibrutinib and novel BTK inhibitors in clinical development
J Hematol Oncol
Date: 08 2013

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
J Hematol Oncol
Date: 11 2013

STAT inhibitors for cancer therapy
J Hematol Oncol
Date: 12 2013

Ibrutinib and indolent B-cell lymphomas
Clinical Lymphoma Myeloma and Leukemia
Date: 08 2014

Novel ALK inhibitors in clinical use and development
J Hematol Oncol
Date: 01 2015

Novel agents for advanced pancreatic cancer.
Oncotarget
Date: 02 2015

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Journal of Hematology & Oncology
2019; 12: 92.
Date: 09 2019
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6729004/